Innoviva, Inc. (INVA)

NASDAQ: INVA · IEX Real-Time Price · USD
12.88
-0.03 (-0.23%)
Nov 29, 2022 4:00 PM EDT - Market closed
-0.23%
Market Cap 900.90M
Revenue (ttm) 373.22M
Net Income (ttm) 292.58M
Shares Out 69.73M
EPS (ttm) 3.32
PE Ratio 3.88
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 357,187
Open 12.85
Previous Close 12.91
Day's Range 12.79 - 12.98
52-Week Range 11.57 - 20.71
Beta 0.59
Analysts Sell
Price Target 17.85 (+38.6%)
Earnings Date Nov 9, 2022

About INVA

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has... [Read more]

Industry Pharmaceuticals
IPO Date Oct 5, 2004
CEO Pavel Raifeld
Employees 5
Stock Exchange NASDAQ
Ticker Symbol INVA
Full Company Profile

Financial Performance

In 2021, Innoviva's revenue was $391.87 million, an increase of 16.35% compared to the previous year's $336.79 million. Earnings were $265.85 million, an increase of 18.47%.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for INVA stock is "Sell." The 12-month stock price forecast is 17.85, which is an increase of 38.59% from the latest price.

Price Target
$17.85
(38.59% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Should Value Investors Buy Innoviva (INVA) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...

1 day ago - Zacks Investment Research

5 Value Stocks With Attractive EV-to-EBITDA Ratios to Snap Up

We have screened value stocks PBF, INVA, GLP, HCCI and STRL based on the EV-to-EBITDA ratio, which offers a clearer picture of valuation and earnings potential.

Other symbols: GLPHCCIPBFSTRL
1 week ago - Zacks Investment Research

Are Investors Undervaluing Innoviva (INVA) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...

2 weeks ago - Zacks Investment Research

Innoviva (INVA) Q3 Earnings and Revenues Lag Estimates

Innoviva (INVA) delivered earnings and revenue surprises of -78.18% and 81.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Innoviva (INVA) Earnings Expected to Grow: Should You Buy?

Innoviva (INVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ...

--- Presentations Reinforce Topline Safety and Efficacy Findings and Highlight Consistency between Clinical and Microbiological Endpoints --- Presentations Reinforce Topline Safety and Efficacy Findings...

1 month ago - GlobeNewsWire

Surging Earnings Estimates Signal Upside for Innoviva (INVA) Stock

Innoviva (INVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

1 month ago - Zacks Investment Research

Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, toda...

2 months ago - Business Wire

Innoviva Completes Acquisition of La Jolla Pharmaceutical

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, toda...

3 months ago - Business Wire

Innoviva (INVA) Misses Q2 Earnings Estimates

Innoviva (INVA) delivered earnings and revenue surprises of -90.91% and 4.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”), a diversified holding company with a portfolio of royalties and a growing portfolio of healthcare asset...

4 months ago - Business Wire

Earnings Preview: Innoviva (INVA) Q2 Earnings Expected to Decline

Innoviva (INVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests

Theravance Biopharma, Inc. (NASDAQ: TBPH) has agreed to sell all of its units in Theravance Respiratory Company, LLC, representing 85% economic interest in the sales-based royalty rights on worldwide ne...

Other symbols: TBPH
4 months ago - Benzinga

Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million ...

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, toda...

Other symbols: RPRX
4 months ago - Business Wire

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating La Jolla Pharmaceuticals Company Buyout

Wilmington, Delaware--(Newsfile Corp. - July 12, 2022) - Rigrodsky Law, P.A. is investigating La Jolla Pharmaceuticals Company ("La Jolla") (NASDAQ: LJPC) regarding possible breaches of fiduciary duties...

4 months ago - Newsfile Corp

SHAREHOLDER ALERT: Weiss Law Investigates La Jolla Pharmaceutical Company

NEW YORK , July 11, 2022 /PRNewswire/ --  Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of La Jolla Pharmaceutical Company ("La Jol...

4 months ago - PRNewsWire

LA JOLLA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of ...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of La Jolla Pharmaceu...

4 months ago - Business Wire

La Jolla Pharmaceutical (LJPC) Stock Skyrockets on Innoviva Acquisition News

A headline-grabbing takeover deal could be impactful for the medical community - and today, it's definitely huge news for LJPC stock holders. The post La Jolla Pharmaceutical (LJPC) Stock Skyrockets on ...

4 months ago - InvestorPlace

Innoviva Completes Acquisition of Entasis Therapeutics

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties, today announced the successful completion of its acquisition...

4 months ago - Business Wire

Innoviva Bolsters Its Infectious Disease, Hospital Portfolio With La Jolla Deal

Innoviva Inc (NASDAQ: INVA) has agreed to acquire La Jolla Pharmaceutical Company (NASDAQ: LJPC) for $5.95 per share, representing a premium of approximately 70% to the 30-day volume-weighted average pr...

4 months ago - Benzinga

Innoviva to Acquire La Jolla Pharmaceutical Company

BURLINGAME, Calif. & WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, ...

4 months ago - Business Wire

Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis The...

4 months ago - Business Wire

Scott+Scott Attorneys at Law LLP Investigates Innoviva Buyout of Entasis – ETTX

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether the directors of Entasis Therapeuti...

5 months ago - Business Wire